Novartis joins CureVac's vaccine contractor line-up



* Trial read-out expected early in second quarter

* Other partners include Bayer, GSK, Fareva, Rentschler

* Novartis site to come online in summer of 2021

* Novartis to make up to 50 mln doses this year

By Ludwig Burger

FRANKFURT, March 4 (Reuters) - German biotech firm CureVac 5CV.DE has enlisted Swiss pharmaceutical giant Novartis NOVN.S to help produce its experimental COVID-19 vaccine, boosting a network of contract manufacturers ahead of results from a pivotal trial.

Novartis plans to manufacture the mRNA molecules the two-shot vaccine is based on as well as "bulk drug product" for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022, the two companies said on Thursday.

Delivery from the manufacturing site in Kundl, Austria, is expected to start in summer 2021, they said.

CureVac expects initial results from its late-stage trial early in the second quarter rather than this month because the biotech company plans to publish read-outs for specific variants, a spokesman said.

"We need a certain number of cases for each virus variant to arrive at statistically significant results," he said.

Variants that are on the rise in South Africa and Brazil in particular have raised concerns about a potential loss in vaccine efficacy.

Novartis joins a list of CureVac partners for manufacturing and filling vials that include Bayer BAYGn.DE , family-owned Fareva of France, Wacker WCHG.DE and Rentschler Biopharma SE.

Britain's GlaxoSmithKline GSK.L , which is working with CureVac on next-generation vaccines that target several coronavirus variants with one shot, will also help with production this year.

CureVac, which began late-stage testing of the vaccine in December, reiterated that it aims to produce up to 300 million doses in 2021 and 600 million to 1 billion doses in 2022.
Reporting by Ludwig Burger; Editing by Thomas Escritt, Emma Thomasson and David Clarke

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.